Biotechnologies et industrie pharmaceutique. Un modèle évolutionnaire conforme à l'histoire

Franco Malerba, Luigi Orsenigo and Sandrine Selosse

Revue de l'OFCE, 2006, vol. 96, issue 1, 157-209

Abstract: This paper is a first attempt at modelling the long term dynamics of market structure and innovation in the pharmaceutical industry in a history-friendly way. The model examines the relationships between the nature of the search space, demand, the patterns of competition and industry evolution in the age of random screening and in the age of molecular biology, and shows that concentration in the pharmaceutical industry is shaped by lack of cumulativeness in innovative activities and market fragmentation. The model conforms to our appreciative understanding and responds to changes in parameters concerning demand, costs, economies of scale, opportunity conditions and the relative advantages of New Biotechnology Firms (NBFs) vis-à-vis incumbents. With the exception of costs increases, the model is quite robust to these changes in its essential features: it is quite difficult to raise substantially concentration and to have NBFs displacing incumbents. JEL codes: L1, L65.

JEL-codes: L1 L65 (search for similar items in EconPapers)
Date: 2006
References: Add references at CitEc
Citations:

Downloads: (external link)
http://www.cairn.info/load_pdf.php?ID_ARTICLE=REOF_096_0157 (application/pdf)
http://www.cairn.info/revue-de-l-ofce-2006-1-page-157.htm (text/html)
free

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:cai:reofsp:reof_096_0157

Access Statistics for this article

More articles in Revue de l'OFCE from Presses de Sciences-Po
Bibliographic data for series maintained by Jean-Baptiste de Vathaire ().